Innovation in pharmaceuticals, medical devices, diagnostic and digital health technologies has transformed the way we deliver and manage treatments and organize healthcare systems. The challenges in uptake of integrated technologies may hinder patient access to new treatment options, potentially affecting patient outcomes and stifling innovation and commercial success in the European life sciences sector. To better understand the factors that can limit access to transformative technologies, CRA consultants, in collaboration with members of the American Chamber of Commerce to the European Union (AmCham EU) recently analyzed these challenges and opportunities.
To access the full article, click the link below.
CRA's RADAR Insights: Impact of US pricing strategies on orphan drug pricing in Germany - Part 3
In Part 3 of this series, RADAR data on orphan-drug pricing in Germany revealed a significant increase in manufacturer-set list prices for new orphan drugs...